Skip to Content
Merck
CN

SML0623

Iniparib

≥98% (HPLC)

Synonym(s):

4-Iodo-3-nitrobenzamide, BSI-201

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C7H5IN2O3
CAS Number:
Molecular Weight:
292.03
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear

storage temp.

room temp

InChI

1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)

InChI key

MDOJTZQKHMAPBK-UHFFFAOYSA-N

General description

Iniparib is also called as BSI-201. It is an anticancer agent.

Biochem/physiol Actions

4-iodo-3-nitrobenzamide, the intracellular metabolite of iniparib has the capability to covalently prevent PARP1 (poly(ADP-Ribose) polymerase 1) under cell-free conditions. PARP inhibitor also plays a role in BRCA (breast cancer susceptibility protein) deficient tumors.
Iniparib (BSI-201) is an antineoplastic originally thought to be a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor. Recent studies indicate Iniparib is not a PARP-1 inhibitor, and its mechanism of action is currently unknown.
Iniparib (BSI-201) is an antineoplastic.


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
O'Shaughnessy J, et al.
The New England Journal of Medicine, 364(3), 205-214 (2011)
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Fogelman DR, et al.
Anticancer Research, 31(4), 1417-1420 (2011)
Failure of iniparib to inhibit poly (ADP-Ribose) polymerase in vitro.
Patel AG, et al.
Clinical Cancer Research, 18(6), 1655?1662-1655?1662 (2012)



Global Trade Item Number

SKUGTIN
SML0623-10MG04061832925851
SML0623-50MG04061832925868